A phase II trial found that neoadjuvant camrelizumab plus apatinib, a chemotherapy-free combination of immunotherapy and anti-angiogenic therapy, produced manageable ...
A real-world study of 87 patients suggests that combining Trop-2 antibody-drug conjugates with PD-1 inhibitors and anti-angiogenic therapy substantially improves ...
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!
